Skip to main content

Table 1 Baseline characteristics of patients in COVID-19 phase and pre-COVID-19 phase

From: Active surveillance with telemedicine in patients on anticoagulants during the national lockdown (COVID-19 phase) and comparison with pre-COVID-19 phase

Clinical characteristic Pre-COVID phase COVID phase p value
Patient (n) 614 600  
Age (in years) + SD 55.27 ± 17.09 56.97 ± 15.09 0.56
Sex (M/F) 402/212 378/222 0.37
Rural (n, %) 387 (63.03) 398 (66.34) 0.23
Urban (n, %) 227 (36.97) 202 (33.67)
HTN (n, %) 238 (38.76) 218 (36.33) 0.40
Diabetes (n, %) 213 (34.6) 189 (31.5) 0.24
CKD (n,%) 73 (11.88) 54 (9) 0.11
CAD (n, %) 205 (33.38) 189 (31.5) 0.50
Indication of OAC
 Atrial fibrillation (n, %) 156 (25.4) 174 (29) 0.17
 Prosthetic valve (n, %) 254 (41.3) 232 (38.7) 0.34
 Pulmonary thromboembolism (n, %) 117 (19.1) 101 (16.9) 0.33
 Other (n, %) 87 (14.16) 93 (15.5) 0.46
Drugs
 OAC (n, %) 525 (86.6) 506 (84.4) 0.57
 NOAC (n, %) 89 (14.4) 94 (15.6) 0.57
 Antiplatelets (n, %) 267 (43.48) 218 (36.33) 0.01
  1. OAC oral anticoagulants-warfarin and nicoumalone, HTN hypertension, CKD chronic kidney disease, CAD coronary artery disease